Published the monthly exercise status for September 2026 of the 70th and 71st stock acquisition rights. Number of shares granted: 4,300,000 shares; number of rights actually exercised in September: 43,000; ratio to total issued: 9.0%; unexercised rights: 437,000; exercise restriction: 5.4% (based on listing rules).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SymBio Pharmaceuticals Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4582-20261001-01.pdf","jir_short_summary":"Published the monthly exercise status for September 2026 of the 70th and 71st stock acquisition rights. Number of shares granted: 4,300,000 shares; number of rights actually exercised in September: 43,000; ratio to total issued: 9.0%; unexercised rights: 437,000; exercise restriction: 5.4% (based on listing rules).","jir_summary":"### Overview of Exercise Status of Stock Acquisition Rights\n\n\n### Impact and Background\nFor details on the operation of stock acquisition rights with an exercise price adjustment clause, refer to the notice related to the unsecured bond facility agreement. The monthly exercise ratio, as an indicator of potential dilution risk to the market, has generally remained low. Meanwhile, the rights allocated to the EVO FUND have special restrictions, and future exercise trends may vary depending on contractual conditions and timing of instructions.","jir_financial_highlights":"Number of shares granted: 4,300,000 shares (Unknown)\nNumber of stock acquisition rights exercised: 43,000 items (Unknown)\nNew shares (shares): Unknown (Unknown)","jir_category":"","jir_hashtags":"#SymBioPharmaceuticals, #StockAcquisitionRights, #StockOptions","jir_key_figures":"Number of shares granted: 4,300,000 shares\nNumber of stock acquisition rights exercised: 43,000 items\nNumber of unexercised stock acquisition rights: 437,000 items","jir_meta_title":"SymBio Pharmaceuticals Limited - Monthly Exercise Status of Third-Party Allotted Stock Acquisition Rights | September 2026","jir_meta_description":"Disclosure of the September monthly exercise status for the 70th and 71st stock acquisition rights of SymBio Pharmaceuticals Limited. Shares granted: 4,300,000 shares; exercised: 43,000 items; unexercised: 437,000 items; exercise restriction: 5.4%. Note contractual terms and future trends.","jir_og_title":"SymBio Pharmaceuticals Limited - September Monthly Exercise Status of Stock Acquisition Rights","jir_og_description":"Published the September exercise status of the 70th and 71st stock acquisition rights. Exercised: 43,000 items; unexercised: 437,000 items; ratio to total issued shares: 9.0%.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60013,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-126360","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n